Riskpilot← Back to searchSign inGet full accessAcrosomen Aktiebolag
ABActiveOrg 5564724630Tomtebogatan 21 A 5tr Lgh 1501Medical specialists activities · NACE 8622Est. 19931 employees
Revenue 2025
SEK 1K
-99% vs 2024
EBITDA margin
-3100.0%
-875% vs 2024
Equity ratio
86.4%
Financial strength
Net profit 2025
SEK -31K
-875% vs 2024
| Revenue | SEK 1K | -99% |
| EBITDA | SEK -31K | -875% |
| Net profit | SEK -31K | -875% |
| Total assets | SEK 147K | -18% |
| Equity | SEK 127K | -19% |
| Employees | 1 | — |
Legal name
Acrosomen Aktiebolag
Org number
5564724630
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
1 oktober 1993
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva läkarverksamhet utföra utvecklings- och konsultationsarbete inom det medicinska området och bedriva handel med licenser och patent och därmed jämförbar verksamhet. Därutöver ska bolaget också äga och förvalta lös och fast egendom särskilt föremål av historiskt och kulturellt värde.
Address
Tomtebogatan 21 A 5tr Lgh 1501
Phone
+46705934961
Email
stefan.arver@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 251 | 219 | 182 | 78 | 1 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 68 | 107 | 42 | 4 | −31 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 68 | 107 | 42 | 4 | −31 |
| Net financials | — | — | — | 1 | — |
| Profit before tax | 248 | 107 | 42 | 5 | −31 |
| Tax | −56 | −22 | −9 | −1 | −0 |
| Net profit | 192 | 85 | 33 | 4 | −31 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 673 | 514 | 566 | 180 | 147 |
| Equity | 331 | 206 | 154 | 157 | 127 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 343 | 308 | 413 | 23 | 20 |
| Total debt | 343 | 308 | 413 | 23 | 20 |
EBITDA margin
-3100.0%
This company
15.8%
Market median
-19720% vs market
20212025
Equity ratio
86.4%
This company
38.2%
Market median
+126% vs market
20212025
Return on equity
-24.4%
This company
18.4%
Market median
-233% vs market
20212025
Net profit margin
-3100.0%
This company
8.1%
Market median
-38372% vs market
20212025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20212025
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TS Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Acrosomen Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tord Stefan Erik Arver | Chief Executive Officer | 0 companies |
| Erik Waste Johannes Arver | Deputy Board Member | 0 companies |